Art. -Nr.: HY-19930

Copy Link Print Information

Vaborbactam

(Synonyms: RPX7009)

42 Cited Publications

Kundenbewertung

Based on 42 publication(s) in Google Scholar

Vaborbactam (RPX7009) is a cyclic boronic acid pharmacophore β-lactamase inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.65%
CAS. Nr.: 1360457-46-0
Formel: C₁₂H₁₆BNO₅S
Molecular Weight:297.14

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Vaborbactam Chemical Structure

CAS. Nr.: 1360457-46-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (42)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Vaborbactam (RPX7009) is a cyclic boronic acid pharmacophore β-lactamase inhibitor.

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen :

In Vitro

Vaborbactam is a broad spectrum of inhibition of β-lactamases, with particularly potent activity against KPC, CTX-M, SHV, and CMY enzymes^[1]. Vaborbactam restores SM 7338 activity for 72.7 to 98.1% of CPE isolates at ≤2 μg/mL, and maximum potentiation is achieved with fixed concentrations of ≥8 μg/mL of the inhibitor (≥96.5% of isolates are inhibited at ≤2 μg/mL of SM 7338-vaborbactam). SM 7338-vaborbactam with a fixed concentration of 8 μg/mL of the inhibitor (MIC50, ≤0.06 μg/mL for all organisms) inhibits 93.7% of the CPE isolates displaying elevated SM 7338 MICs at ≤1 μg/mL^[2]. By forming a reversible dative bond with the blactamase, vaborbactam acts as a competitive inhibitor and is not hydrolyzed by the b-lactamase^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vaborbactam is well tolerated and has a half-life of 1.23 h, and steadystate volume of distribution of 21.0 L in subjects^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1360457-46-0
Appearance Solid
Molecular Weight 297.14
Formel C₁₂H₁₆BNO₅S
Color Light brown to yellow
SMILES

O=C(O)C[C@@H]1CC[C@H](NC(CC2=CC=CS2)=O)B(O)O1
Synonyms

RPX7009
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (42)

All Bio/Physico-chemical AssayMicrobiological Assay

Sort by:

Journal Impact Factor

Nature

Blood culture-free ultra-rapid antimicrobial susceptibility testing. [Abstract]

2024 Aug;632(8026):893-902. PMID: 39048820
J Med Chem

High-Throughput Crystallography Reveals Boron-Containing Inhibitors of a Penicillin-Binding Protein with Di- and Tricovalent Binding Modes. [Abstract]

2021 Aug 12;64(15):11379-11394. PMID: 34337941
Pharmaceutics

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. [Abstract]

2023 Nov 30;15(12):2705. PMID: 38140046
J Clin Microbiol

NitroSpeed-Carba NP Test for Rapid Detection and Differentiation between Different Classes of Carbapenemases in Enterobacterales. [Abstract]

2020 Aug 24;58(9):e00932-20. PMID: 32580949

Vaborbactam purchased from MedChemExpress. Usage Cited in: J Clin Microbiol. 2020 Aug 24;58(9):e00932-20. [Abstract]

100 μl of a Tris-HCl 20 mmol/liter lysis buffer containing 0.1 mM ZnSO4 and vaborbactam (50 μg/ml; MedChemExpress; reference no. HY-19930) in tube 5.A color change from yellow to red in tube 1 only containing water and the absence of any color change (no hydrolysis of nitrocefin) in the other tubes 2 to 5 indicate lack of carbapenemase activity but production of a noncarbapenemase β-lactamase, such as TEM-1 or CTX-M-type enzymes.
Antibiotics (Basel)

2024 May 1, 13(5), 416.
Antibiotics (Basel)

Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]

2021 Nov 3;10(11):1341. PMID: 34827279
Antibiotics (Basel)

Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]

2021 Sep 14;10(9):1110. PMID: 34572692

Vaborbactam purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]

HEPES buffer or plasma samples spiked with 100 mg/L of meropenem, 100 mg/L of Vaborbactam or the mixture of them were subjected to the NDM-1 biosensor; the activity responses (mV) of the NDM-1 biosensor to each agent spiked in HEPES and the net activity response (∆mV) of the NDM-1 biosensor to each agent spiked in plasma are shown in panel.
Int J Antimicrob Agents

MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]

2024 May 14:107206. PMID: 38754526
Int J Antimicrob Agents

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. [Abstract]

2021 Nov;58(5):106439. PMID: 34547421

Vaborbactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2021 Nov;58(5):106439. [Abstract]

The β-lactamase L2 of S. maltophilia seemed overall the most susceptible to BLIs, with sulbactam and tazobactam lowering MICATM to 4–8 µg/mL, Vaborbactam (VAB; 0-32 μg/mL) to 2 µg/mL, and AVI and REL, the most effective BLIs, lowered MIC ATM to ≤1 µg/mL.
Spectrochim Acta A Mol Biomol Spectrosc

Spectral signal processing approaches for selective quantification of the recently FDA approved brand-new combination of Vaborbactam and Meropenem; for conformity assessment of bulk and batch release. [Abstract]

2020 Apr 5;230:118066. PMID: 31958602
Int J Infect Dis

Evaluation of NitroSpeed-Carba NP test for rapid identification among different classes of carbapenemases in Enterobacterales and Pseudomonas aeruginosa. [Abstract]

2021 May:106:415-420. PMID: 33864920
iScience

The oxacillinase variant, OXA-1152, in Pandoraea sputorum contributes to discrepancies in carbapenem resistance. [Abstract]

2025 Mar 28;28(5):112311. PMID: 40454099
ACS Infect Dis

3- O-Substituted Quercetin: an Antibiotic-Potentiating Agent against Multidrug-Resistant Gram-Negative Enterobacteriaceae through Simultaneous Inhibition of Efflux Pump and Broad-Spectrum Carbapenemases. [Abstract]

2024 May 10;10(5):1624-1643. PMID: 38652574
ACS Infect Dis

Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relationships and In Vitro and In Vivo Activities. [Abstract]

2022 Mar 11;8(3):400-410. PMID: 35112852
ACS Infect Dis

Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. [Abstract]

2021 Apr 9;7(4):826-837. PMID: 33723985
Antimicrob Agents Chemother

Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]

2026 Jun 3;70(6):e0126725. PMID: 42053451
Antimicrob Agents Chemother

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model. [Abstract]

2026 Feb 19:e0136525. PMID: 41711574
Antimicrob Agents Chemother

Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model. [Abstract]

2025 Sep 3;69(9):e0001725. PMID: 40741958
Antimicrob Agents Chemother

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [Abstract]

2025 Jun 2:e0010825. PMID: 40455008
Antimicrob Agents Chemother

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]

2024 Nov 6;68(11):e0077524. PMID: 39365068
Antimicrob Agents Chemother

Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. [Abstract]

2024 Aug 19:e0069324. PMID: 39158279
Antimicrob Agents Chemother

In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. [Abstract]

2023 Dec 14;67(12):e0034623. PMID: 37971240
Antimicrob Agents Chemother

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]

2023 Jul 18;67(7):e0033923. PMID: 37255469
Antimicrob Agents Chemother

Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. [Abstract]

2020 Nov 17;64(12):e00297-20. PMID: 32928733
Antimicrob Agents Chemother

Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae. [Abstract]

2020 Sep 21;64(10):e00409-20. PMID: 32660988
Antimicrob Agents Chemother

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens. [Abstract]

2020 Mar 24;64(4):e02255-19. PMID: 31932381
Antimicrob Agents Chemother

In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates. [Abstract]

2019 Feb 26;63(3). pii: e02623-18. PMID: 30642943
Antimicrob Agents Chemother

Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. [Abstract]

2018 Jul 27;62(8). pii: e00414-18. PMID: 29760136
J Antimicrob Chemother

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]

2026 Feb 2;81(3):dkag034. PMID: 41648989
J Antimicrob Chemother

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales. [Abstract]

2023 Oct 3;78(10):2428-2434. PMID: 37584236
J Antimicrob Chemother

In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]

2021 Jul 15;76(8):2071-2078. PMID: 33956969
J Antimicrob Chemother

Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]

2021 Feb 11;76(3):653-658. PMID: 33258923
Open Forum Infect Di

In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient. [Abstract]

2020 Jan 4;7(1):ofz545. PMID: 31993456
Bioorg Med Chem

A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. [Abstract]

2021 Sep 15:46:116343. PMID: 34450571
Eur J Clin Microbiol Infect Dis

In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]

2025 Mar;44(3):571-585. PMID: 39704920
Eur J Clin Microbiol Infect Dis

In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]

2025 Feb;44(2):277-284. PMID: 39589655
Infect Drug Resist

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China. [Abstract]

2021 Jun 30;14:2499-2507. PMID: 34234477
bioRxiv

2025 Nov 27.
Seoul National University

2025 Feb.
bioRxiv

2025 January 21.
bioRxiv

2021 Mar 13.
RSC Med Chem

Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition. [Abstract]

2020 Jan 10;11(4):491-496. PMID: 33479650

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 5.26 mg/mL (17.70 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3654 mL

16.8271 mL

33.6542 mL

5 mM

0.6731 mL

3.3654 mL

6.7308 mL

10 mM

0.3365 mL

1.6827 mL

3.3654 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 108 mM Sodium carbonate 中最大溶解度

Solubility: 25 mg/mL (84.14 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.62 mg/mL (8.82 mM); Clear solution

Protocol 3

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.62 mg/mL (8.82 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 27.5 mg/mL (92.55 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hecker SJ, et al. Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem. 2015 May 14;58(9):3682-92. [Content Brief]

[2]. Castanheira M, et al. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with SM 7338 against Serine Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8. [Content Brief]

[3]. Wong D, et al. Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	3.3654 mL	16.8271 mL	33.6542 mL	84.1354 mL
	5 mM	0.6731 mL	3.3654 mL	6.7308 mL	16.8271 mL
	10 mM	0.3365 mL	1.6827 mL	3.3654 mL	8.4135 mL
	15 mM	0.2244 mL	1.1218 mL	2.2436 mL	5.6090 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Vaborbactam

42 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Vaborbactam

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

EMA-Approved Drug Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Vaborbactam

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (42)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Vaborbactam

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

EMA-Approved Drug Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Vaborbactam

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (42)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Vaborbactam Related Classifications

HY-19930 Related Classifications